Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2025)

Contineum Therapeutics' Gains from Investment Securities history spans 3 years, with the latest figure at -$303000.0 for Q4 2025.

  • Quarterly Gains from Investment Securities fell 105.5% to -$303000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, down 11.42% year-over-year, with the annual reading at -$3000.0 for FY2025, 100.07% down from the prior year.
  • Gains from Investment Securities came in at -$303000.0 for Q4 2025, down from $5.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.6 million in Q3 2025 to a low of -$303000.0 in Q4 2025.
  • The 3-year median for Gains from Investment Securities is $400000.0 (2023), against an average of $2.3 million.
  • Year-over-year, Gains from Investment Securities plummeted 450.0% in 2024 and then soared 50832.84% in 2025.
  • Contineum Therapeutics' Gains from Investment Securities stood at -$33000.0 in 2023, then soared by 16806.06% to $5.5 million in 2024, then plummeted by 105.5% to -$303000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTNM's Gains from Investment Securities are -$303000.0 (Q4 2025), $5.6 million (Q3 2025), and $5.6 million (Q2 2025).